Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study

Peter Bergman, Anna-Carin Norlin, Susanne Hansen, Rokeya Sultana Rekha, Birgitta Agerberth, Linda Björkhem-Bergman, Lena Ekström, Jonatan D Lindh, Jan Andersson, Peter Bergman, Anna-Carin Norlin, Susanne Hansen, Rokeya Sultana Rekha, Birgitta Agerberth, Linda Björkhem-Bergman, Lena Ekström, Jonatan D Lindh, Jan Andersson

Abstract

Background: Low serum levels of 25-hydroxyvitamin D(3) are associated with an increased risk of respiratory tract infections (RTIs). Clinical trials with vitamin D(3) against various infections have been carried out but data are so far not conclusive. Thus, there is a need for additional randomised controlled trials of effects of vitamin D(3) on infections.

Objective: To investigate if supplementation with vitamin D(3) could reduce infectious symptoms and antibiotic consumption among patients with antibody deficiency or frequent RTIs.

Design: A double-blind randomised controlled trial.

Setting: Karolinska University Hospital, Huddinge.

Participants: 140 patients with antibody deficiency (selective IgA subclass deficiency, IgG subclass deficiency, common variable immune disorder) and patients with increased susceptibility to RTIs (>4 bacterial RTIs/year) but without immunological diagnosis.

Intervention: Vitamin D(3) (4000 IU) or placebo was given daily for 1 year.

Primary and secondary outcome measures: The primary endpoint was an infectious score based on five parameters: symptoms from respiratory tract, ears and sinuses, malaise and antibiotic consumption. Secondary endpoints were serum levels of 25-hydroxyvitamin D(3), microbiological findings and levels of antimicrobial peptides (LL-37, HNP1-3) in nasal fluid.

Results: The overall infectious score was significantly reduced for patients allocated to the vitamin D group (202 points) compared with the placebo group (249 points; adjusted relative score 0.771, 95% CI 0.604 to 0.985, p=0.04).

Limitations: A single study centre, small sample size and a selected group of patients. The sample size calculation was performed using p=0.02 as the significance level whereas the primary and secondary endpoints were analysed using the conventional p=0.05 as the significance level.

Conclusions: Supplementation with vitamin D(3) may reduce disease burden in patients with frequent RTIs.

Figures

Figure 1
Figure 1
Study outline.
Figure 2
Figure 2
Primary endpoint. The adjusted total relative infectious score (A) is expressed ‘per quarter’ (3-month periods). The adjusted 1-year scores (total score, airway, malaise, ear, sinus and antibiotics) are depicted in a Forest-plot (B) together with 95% CI. Effects are presented as relative scores (total score, airway and malaise) or OR (ear, sinus, antibiotics and indicated with asterisks).
Figure 3
Figure 3
Secondary endpoint. Vitamin D levels. Serum was collected at days 0, 3, 6, 9 and 12 months and levels of 25-hydroxyvitamin D3 were measured. Values are expressed as mean±95% CI.

References

    1. Hess AF, Unger LJ, Pappenheimer AM. Experimental rickets in rats. III. The prevention of rickets in rats by exposure to sunlight. J Biol Chem 1922;50:77–81
    1. Holick MF, MacLaughlin JA, Clark MB, et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 1980;210:203–5
    1. Holick MF. Vitamin D deficiency. N E J M 2007;357:266–81
    1. Hansdottir S, Monick MM. Vitamin D effects on lung immunity and respiratory diseases. Vitam Horm 2011;86:217–37
    1. Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol 2011;7:337–45
    1. Gibney KB, MacGregor L, Leder K, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis 2008;46:443–6
    1. Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci USA 2011;108:19013–17
    1. Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000;355:618–21
    1. Ginde AA, Mansbach JM, Camargo CA., Jr Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Inter Med 2009;169:384–90
    1. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770–3
    1. Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008;324:23–33
    1. Lemire JM, Archer DC, Beck L, et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995;125(6 Suppl):1704S–8S
    1. Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010;120:3242–54
    1. Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc 2012;71:50–61
    1. Yamshchikov AV, Desai NS, Blumberg HM, et al. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009;15:438–49
    1. Wejse C, Gustafson P, Nielsen J, et al. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 2008;40:111–20
    1. Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006;260:93–101
    1. Dubos F, De la Rocque F, Levy C, et al. Sensitivity of the bacterial meningitis score in 889 children with bacterial meningitis. J Pediatr 2008;152:378–82
    1. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204–10
    1. Laaksi I, Ruohola JP, Mattila V, et al. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men. J Infect Dis 2010;202:809–14
    1. Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect 2009;137:1396–404
    1. Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010;91:1255–60
    1. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011;377:242–50
    1. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012;156:105–14
    1. Lindh JD, Andersson ML, Eliasson E, et al. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metab Dispos 2011;39:933–7
    1. Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta medica Indonesiana 2006;38:3–5
    1. Thijs W, Janssen K, Verhoosel RM, et al. Effect of vitamin D treatment on antimicrobial peptides in asthma pathients and healthy controls, Conference Abstract, European Respiratory Society, 2011.
    1. Cederlund A, Olliver M, Rekha RS, et al. Impaired release of antimicrobial peptides into nasal fluid of hyper-IgE and CVID patients. PLoS One 2011;6:e29316.
    1. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909–12
    1. Olsen K, Falch BM, Danielsen K, et al. Staphylococcus aureus nasal carriage is associated with serum 25-hydroxyvitamin D levels, gender and smoking status. The Tromso Staph and Skin Study. Eur J Clin Microbiol Infect Dis 2012;31:465–73
    1. Khoo AL, Chai LY, Koenen HJ, et al. 1,25-Dihydroxyvitamin D3 modulates cytokine production induced by Candida albicans: impact of seasonal variation of immune responses. J Infect Dis 2011;203:122–30
    1. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol 2011;50:194–200
    1. Hansdottir S, Monick MM, Lovan N, et al. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. J Immunol 2010;184:965–74
    1. Sabetta JR, DePetrillo P, Cipriani RJ, et al. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One 2010;5:e11088.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다